{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:53:33Z","timestamp":1767844413491,"version":"3.49.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jaad.2023.05.095","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:29:00Z","timestamp":1687793340000},"page":"e181-e185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to the feasibility of Kreher et\u00a0al\u2019s \u201cRisk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors\u201d"],"prefix":"10.1016","volume":"89","author":[{"given":"Katelyn J.","family":"Rypka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mansh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2023.05.095_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.095_bib2","doi-asserted-by":"crossref","first-page":"373e","DOI":"10.1097\/PRS.0000000000004696","article-title":"Current basal and squamous cell skin cancer management","volume":"142","author":"Mendez","year":"2018","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.095_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaad.2017.11.033","article-title":"Estimating the cost of skin cancer detection by dermatology providers in a large health care system","volume":"78","author":"Matsumoto","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2023.05.095_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.2023.4342","article-title":"Screening for skin cancer: US preventive services task force recommendation statement","volume":"329","author":"Mangione","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222301188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222301188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:38Z","timestamp":1759274918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222301188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S019096222301188X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.095","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to the feasibility of Kreher et\u00a0al\u2019s \u201cRisk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}